Page last updated: 2024-12-05

trichloroacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6421
CHEMBL ID14053
CHEBI ID30956
SCHEMBL ID3220
MeSH IDM0021920

Synonyms (144)

Synonym
MLS001066365
smr000059159
CHEBI:30956 ,
nsc215204
nsc-215204
NCI60_006100
NCIOPEN2_000772
trichloroacetic acid, puriss. p.a., acs reagent, >=99.5%
acide trichloracetique
trichloroethanoic acid
trichloroacetic acid solid
trichloorazijnzuur
nsc77363
aceto-caustin
wln: qvxggg
amchem grass killer
trichloracetic acid
nsc-77363
trichloressigsaeure
acido tricloroacetico
acetic acid, trichloro- (solid)
acetic acid, trichloro-
inchi=1/c2hcl3o2/c3-2(4,5)1(6)7/h(h,6,7
NCGC00091021-02
NCGC00091021-01
epa pesticide chemical code 081002
kyselina trichloroctova [czech]
trichloressigsaeure [german]
caswell no. 870
hsdb 1779
trichloorazijnzuur [dutch]
konesta
tca [bsi:iso]
tecane
trichloromethanecarboxylic acid
nsc 215204
un1839
ccris 4015
acido tricloroacetico [italian]
un2564
einecs 200-927-2
ai3-24157
trichloroacetic acid (iupac)
acide trichloracetique [french]
brn 0970119
76-03-9
trichloroacetic acid
TCA ,
trichloroacetic acid, >=99.0% (titration)
trichloroacetic acid, acs reagent, >=99.0%
trichloroacetic acid, bioxtra, >=99.0%
trichloroacetic acid, biotech. grade, redistilled, >=99%
acid, trichloroacetic
tcaa
trichloracetique, acide
MLS001336034
MLS001336033
2,2,2-trichloroacetic acid
trichloroacetic acid, bioultra, >=99.5% (t)
trichloroacetic acid, acs reagent, for the determination of fe in blood according to heilmeyer, >=99.5%
CHEMBL14053
acido tricloroacetico (tn)
D08633
T0369
AKOS000118939
NCGC00091021-03
NCGC00091021-04
NCGC00254060-01
tox21_201632
NCGC00259181-01
tox21_300187
STL163550
cas-76-03-9
tox21_111060
dtxcid001378
dtxsid1021378 ,
HMS2233M06
acetic acid, 2,2,2-trichloro-
kyselina trichloroctova
ec 200-927-2
4-02-00-00508 (beilstein handbook reference)
unii-5v2jdo056x
5v2jdo056x ,
trichloroacetic acid [un1839] [corrosive]
trichloroacetic acid [usp]
FT-0645145
tca [iso]
trichloroacetic acid [mi]
trichloroacetic acid [ep monograph]
trichloroacetic acid [ep impurity]
trichloroacetic acid [vandf]
trichloroacetic acid [who-dd]
trichloroacetic acid [hsdb]
trichloroacetic acid [mart.]
HMS3374M09
SCHEMBL3220
trichloro acetic acid
ccl3co2h
ccl3cooh
perchloroacetic acid
tricloroacetic acid
un 1839
un 2564 (salt/mix)
tkhuk
varitox (salt/mix)
na ta (salt/mix)
tkhu
mfcd00004177
J-525058
F1908-0096
tca deblock, 3 % (w/v) in methylene chloride
trichloroacetic acid, purum p.a., >=99.0% (t)
trichloroacetic acid, pestanal(r), analytical standard
trichloroacetic acid, reagent grade, 98%
trichloroacetic acid, >=99.5%
trichloroacetic acid, jis special grade, >=99.0%
trichloroacetic acid, acs reagent
trichloroacetic acid; 2,2,2-trichloroacetic acid
trichloorazijnzuur (dutch)
trichloressigsaure
trichloroacetic acid solid (dot)
trichloroacetic acid (acd/name 4.0)
acide trichloracetique (french)
trichloressigsaeure (german)
acido tricloroacetico (italian)
trichloro-acetic acid
Q410116
STR02719
trichloroacetic-acid
E78851
trichloroacetic acid 100 microg/ml in methyl-tert-butyl ether
EN300-19248
acetic-1-13c acid, 2,2,2-trichloro- (9ci)
2,2,2-trichloro-acetic acid-13c2 (contain 3.5% unlabeled)
trichloroacetic acid (ep impurity)
trichloroacetic acid 5%
trichloroacetic acid (mart.)
usepa/opp pesticide code: 081002
trichloroacetic acid (ep monograph)
dow sodium tca stabilized
trichloroacetic acid, (solid)
na ta
trichloroaectic acid
Z104473288

Research Excerpts

Overview

Trichloroacetic acid (TCA) is a common non-volatile by-product of chlorination disinfection for drinking water. It has been used for more than 20 years in skin rejuvenation treatments for various skin conditions.

ExcerptReferenceRelevance
"Trichloroacetic acid (TCA) is a chemical tissue-destroying agent used as a highly concentrated solution for wart management."( Towards Formulation of Highly Acidic Active Ingredients: Development of Clinically Effective Concentrated Trichloroacetic Acid Gel for Wart Management.
Abdel-Wahab, HM; Abouelmagd, SA; Ahmed, SS; Helmy, AM; Sabaa, RME, 2023
)
1.85
"Trichloroacetic acid (TCA) is an agent widely applied in dermatology for skin regeneration. "( Chemical Regeneration of Wound Defects: Relevance to the Canine Palatal Mucosa and Cell Cycle Up-Regulation in Human Gingival Fibroblasts.
Ben Amara, H; Chung, MA; Koo, KT; Lee, K; Lee, SC; Lee, SW; Leesungbok, R, 2019
)
1.96
"Trichloroacetic acid seems to be a potential, cost-effective, well-tolerated therapeutic option for the treatment of vitiligo in the adults and pediatric populations."( Trichloroacetic Acid in Different Concentrations: A Promising Treatment Modality for Vitiligo.
Alakad, R; Fawzy, MM; Nofal, A, 2021
)
3.51
"Trichloroacetic acid (TCA) is a common non-volatile by-product of chlorination disinfection for drinking water. "( Time-concentration-dependent profile of histone modifications on human hepatocytes treated by trichloroacetic acid.
Lin, H; Peng, X; Wu, F; Yang, J; Yu, S; Zhang, L; Zhang, W; Zhou, C, 2022
)
2.38
"Trichloroacetic acid (TCA) is a nontoxic chemical that has been used for more than 20 years in skin rejuvenation treatments for various skin conditions. "( Efficacy of Silver-based Gel Compared With Fusidic Acid Cream in Topical Treatment Following Trichloroacetic Acid Facial Skin Peeling: A Pilot Study
Gabario, S; Heller, L; Landau, G; Menashe, S; Saadon, H, 2018
)
2.14
"Trichloroacetic acid (TCA) is an oxidative pathway metabolite of TCE."( Assessment of serum S100B and neuron specific enolase levels to evaluate the neurotoxıc effects of organıc solvent exposure.
Tutkun, E; Uysal, S; Yilmaz, FM; Yilmaz, H; Züngün, C,
)
0.85
"Trichloroacetic acid (TCA) is a soft tissue cauterizing agent applied to gingival margins prior to cervical tooth-colored restorations. "( Effect of trichloroacetic acid hydrogel on self-etch adhesive bond strength to dental tissues.
Fathpour, K; Khoroushi, M, 2013
)
2.23
"Trichloroacetic acid (TCA) is a prominent by-product of the chlorination of drinking water. "( Aqueous date fruit extract protects against lipid peroxidation and improves antioxidant status in the liver of rats subchronically exposed to trichloroacetic acid.
Achour, L; Ayed, A; El Arem, A; Ghrairi, F; Saafi, EB; Thouri, A; Zakhama, A; Zekri, M, 2014
)
2.05
"Trichloroacetic acid is a safe and effective agent frequently utilized in dermatologic practice, most commonly in the treatment of verrucae."( Treatment of facial molluscum contagiosum with trichloroacetic acid.
Bard, S; Bellman, B; Connelly, EA; Shiman, MI,
)
1.11
"Trichloroacetic acid is a commonly utilized agent for chemical resurfacing of the face. "( Combination Jessner's solution and trichloroacetic acid chemical peel: technique and outcomes.
Herbig, K; Khosla, RK; Rohrich, RJ; Trussler, AP, 2009
)
2.07
"Trichloroacetic acid (TCAA) is a pollutant with several sources and is also formed naturally in soil. "( Methodological problems in determining TCAA in soils-the discovery of novel natural trichloroacetyl containing compounds and their interference with a common method for determining TCAA in soil and vegetation.
Albers, CN; Hansen, PE; Jacobsen, OS, 2010
)
1.8
"Trichloroacetic acid (TCA) is a common drinking water disinfection byproduct that produces a spectrum of liver effects, including hepatomegaly and liver tumors, in mice. "( Trichloroacetic acid: updated estimates of its bioavailability and its contribution to trichloroethylene-induced mouse hepatomegaly.
Chiu, WA, 2011
)
3.25
"Trichloroacetic acid (TCA) is a contaminant of drinking water. "( Simulation of trichloroacetic acid kinetics in the isolated perfused rat liver using a biologically based kinetic model.
Frazier, JM; Toxopeus, C, 2002
)
2.12
"Trichloroacetic acid (TCA) is a secondary atmospheric pollutant formed by photooxidation of chlorinated solvents in the troposphere--it has, however, recently been ranked among natural organohalogens. "( Uptake, translocation and fate of trichloroacetic acid in a Norway spruce/soil system.
Albrechtová, J; Forczek, ST; Fuksová, K; Matucha, M; Schröder, P; Uhlírová, H, 2003
)
2.04
"Trichloroacetic acid (TCAA) is a member of the family of compounds known as chloroacetic acids, which includes mono-, di- and trichloroacetic acid. "( The ecological effects of trichloroacetic acid in the environment.
Barta, ML; Lewis, TE; Wolfinger, TF, 2004
)
2.07
"Trichloroacetic acid (TCA) is a metabolite of trichloroethylene (TRI) thought to contribute to its hepatocarcinogenic effects in mice. "( Enterohepatic recirculation of trichloroethanol glucuronide as a significant source of trichloroacetic acid. Metabolites of trichloroethylene.
Bull, RJ; Merdink, JL; Springer, DL; Stenner, RD; Stevens, DK, 1997
)
1.96
"Trichloroacetic acid (TCA) is a major metabolite of trichloroethylene (TRI) thought to contribute to its hepatocarcinogenic effects in mice. "( Physiologically-based pharmacokinetic model for trichloroethylene considering enterohepatic recirculation of major metabolites.
Bull, RJ; Fisher, JW; Merdink, JL; Stenner, RD, 1998
)
1.74
"Trichloroacetic acid (TCAA) is a phytotoxic chemical, present throughout the environment. "( A new method for the determination of trichloroacetic acid in spruce foliage and other environmental media.
Cape, JN; Heal, MR; Reeves, NM, 2000
)
2.02
"Trichloroacetic acid, TCA, is a water chlorination by-product similar to dichloroacetic acid, DCA. "( Subacute toxicity of trichloroacetic acid in male and female rats.
Davis, ME, 1990
)
2.04
"Trichloroacetic acid (TCA) is a by-product of the chlorine disinfection of water containing natural organic material. "( Teratogenic activity of trichloroacetic acid in the rat.
Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1989
)
2.03
"Trichloroacetic acid (TCA) is a time-honored peeling agent that has no known systemic toxicity. "( Trichloroacetic acid peels revisited.
Collins, PS, 1989
)
3.16
"Trichloroacetic acid (TCA) is a deliquescent chemical widely used for a variety of procedures. "( Stability-time profile of trichloroacetic acid at various concentrations and storage conditions.
Rumsfield, J; Spinowitz, AL, 1989
)
2.02

Effects

Trichloroacetic acid (TCA) has been detected in rain, snow, and river samples throughout the world. TCA has been tested for mutagenicity in a mouse in vivo system.

ExcerptReferenceRelevance
"Trichloroacetic acid (TCA) has been used for treating acne."( Trichloroacetic Acid Versus Salicylic Acid in the Treatment of Acne Vulgaris in Dark-Skinned Patients.
Abdel Meguid, AM; Elaziz Ahmed Attallah, DA; Omar, H, 2015
)
2.58
"Trichloroacetic acid peels have been described in numerous publications."( Universal Trichloroacetic Acid Peel Technique for Light and Dark Skin.
Fanous, N; Zari, S, 2017
)
1.58
"Trichloroacetic acid (TCA) has been implicated as an airborne pollutant responsible for adverse effects on forest health. "( Long-term exposure of Sitka spruce seedlings to trichloroacetic acid.
Cape, JN; Heal, MR; Reeves, NM; Schröder, P, 2003
)
2.02
"Trichloroacetic acid (TCA) has been detected in rain, snow, and river samples throughout the world. "( Trichloroacetic acid fate and toxicity to the macrophytes Myriophyllum spicatum and Myriophyllum sibiricum under field conditions.
Ellis, DA; Fineberg, NA; Hanson, ML; Mabury, SA; Muir, DC; Sibley, PK; Solomon, KR, 2002
)
3.2
"Trichloroacetic acid (TCA) has been tested for mutagenicity in a mouse in vivo system. "( Relative genotoxicity of trichloroacetic acid (TCA) as revealed by different cytogenetic assays: bone marrow chromosome aberration, micronucleus and sperm-head abnormality in the mouse.
Behera, BC; Bhunya, SP, 1987
)
2.02

Treatment

Trichloroacetic acid (TCA) treatment of the agarose gel after IEF is to be carefully weighed beforehand, because some high molecular mass proteins were less likely to enter the second-dimensional polyacrylamide gel after TCA fixation. The enzyme hydrolysed 2':3'-cMP with an efficiency of about 60%. With rRNA as substrate, it is about 45%.

ExcerptReferenceRelevance
"Trichloroacetic acid treatment of crude nephritogenic glycopeptide mixtures precipitated the heteropolysaccharide glycopeptide of the MG-inducing factor, thus permitting the separation of nephritogenoside from the heteropolysaccharide glycopeptide by a rather simple technique."( Nephritogenic glycoprotein X. Correlation between the purity of nephritogenic glycopeptide, nephritogenoside, and morphological manifestation of glomerulonephritis.
Natori, Y; Shibata, S, 1984
)
0.99
"Trichloroacetic acid (TCA) treatment of the agarose gel after IEF is to be carefully weighed beforehand, because some high molecular mass proteins were less likely to enter the second-dimensional polyacrylamide gel after TCA fixation, and proteins such as mouse skeletal muscle actin gave pseudospots in the agarose 2-DE patterns without TCA fixation."( Preparative two-dimensional gel electrophoresis with agarose gels in the first dimension for high molecular mass proteins.
Maeda, T; Oh-Ishi, M; Satoh, M, 2000
)
1.03
"Trichloroacetic acid treatment of cytosolic fractions indicated that in hepatocyte suspensions, 50-60% of the radiolabel was bound to cytosolic protein."( Uptake and subcellular localization of tritiated dihydro-microcystin-LR in rat liver.
Beasley, VR; Carmichael, WW; Dahlem, AM; Haschek, WM; Hooser, SB; Kuhlenschmidt, MS, 1991
)
1
"The trichloroacetic acid-treated enzyme hydrolysed 2':3'-cCMP with an efficiency of about 60%; while with rRNA as substrate, it is about 45%."( Studies on the enzymatic and physicochemical behaviour of the trichloroacetic acid-treated and untreated bovine pancreatic ribonuclease.
Pandit, MW; Sagar, AJ; Subbiah, V, 1989
)
1
"Trichloroacetic acid treatment of the precursor protein, which is reported to result in removal of the trigger factor that is attached to a precursor protein (Crooke, E., and Wickner, W."( Energy-dependent in vitro translocation of a model protein into Escherichia coli inverted membrane vesicles can take place efficiently in the complete absence of the cytosol fraction.
Matsuyama, S; Mizushima, S, 1989
)
1

Toxicity

ExcerptReferenceRelevance
" Chloroacetic acids are also metabolites of widely used and toxic halogenated hydrocarbons."( Ninety day toxicity study of chloroacetic acids in rats.
Ansari, GA; Bhat, HK; Campbell, GA; Kanz, MF, 1991
)
0.28
" This pattern is consistent with formation of the toxic intermediate in the primary metabolic pathway of each compound."( Delineation of the role of metabolism in the hepatotoxicity of trichloroethylene and perchloroethylene: a dose-effect study.
Buben, JA; O'Flaherty, EJ, 1985
)
0.27
" These results show that interaction of TBA+TCA does bring about alteration in biochemical parameters which may play a pivotal role in toxic responses on long-term exposure."( Administration of subtoxic doses of t-butyl alcohol and trichloroacetic acid to male Wistar rats to study the interactive toxicity.
Acharya, S; Krishnan, S; Mehta, K; Pereira, J; Rao, CV; Rodrigues, S, 1995
)
0.54
" Visible AK were counted, random skin biopsies performed, adverse effects monitored, and patients questioned about preference and perception of efficacy."( A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses.
Cockerell, CJ; Cox, SE; Cruz, PD; Freeman, RG; Lawrence, N, 1995
)
0.53
" In addition, each of the metabolites tested were significantly less developmental toxic than the parent compound, trichloroethylene."( Evaluation of the developmental toxicity of trichloroethylene and detoxification metabolites using Xenopus.
Bantle, JA; Fort, DJ; Hull, M; Rayburn, JR; Stover, EL, 1993
)
0.29
" These results indicated that TCE is metabolized in the male reproductive tract, leading to adverse effects that are more severe in the epididymis than in the testis."( Metabolism and toxicity of trichloroethylene in epididymis and testis.
Forkert, PG; Lash, LH; Nadeau, V; Simmonds, A; Tardif, R, 2002
)
0.31
" The number of Verruca plana lesions and adverse effects were evaluated five times during the treatment (the initial visit, week 2, week 4, week 6, and week 8)."( An open, comparative clinical study on the efficacy and safety of 10% trichloroacetic acid, 25% trichloroacetic acid and cryotherapy for verruca plana.
Cengiz, FP; Emiroglu, N, 2015
)
0.65
" The effective toxic concentrations of the compounds in these cells were found to be 10-fold higher than those producing similar effects in the mouse liver."( Dichloroacetate and Trichloroacetate Toxicity in AML12 Cells: Role of Oxidative Stress.
Hassoun, E; Mettling, C, 2015
)
0.42
" Adverse effects of these chemicals are associated with metabolism to oxidative and glutathione conjugation moieties."( Metabolism and Toxicity of Trichloroethylene and Tetrachloroethylene in Cytochrome P450 2E1 Knockout and Humanized Transgenic Mice.
Fukushima, H; Furuya, S; Iwata, Y; Kosyk, O; Lewis, L; Luo, YS; Rusyn, I; Soldatov, VY; Yoo, HS, 2018
)
0.48
" Also, no major adverse effects were observed in the two groups."( Comparison of efficacy and safety of 30% hydrogen peroxide with 50% trichloroacetic acid in seborrheic keratosis: a randomized controlled study.
Adil, M; Agrawal, D; Amin, SS; Bansal, R; Mohtashim, M; Tabassum, H, 2021
)
0.86

Pharmacokinetics

ExcerptReferenceRelevance
"Previous pharmacokinetic studies with radiolabeled erythropoietin have relied on results of nonspecific methods to derive pharmacokinetic parameters."( A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies.
Modi, NB; Sawyer, ST; Schmidt, RL; Veng-Pedersen, P; Widness, JA, 1992
)
0.28
"The pharmacokinetic profiles of two iodinated human epidermal growth factors (125I-hEGF51 and 125I-hEGF53) in rats receiving a single intravenous dose have been investigated using three independent bioanalytical techniques."( Pharmacokinetic evaluation of two human epidermal growth factors (hEGF51 and hEGF53) in rats.
Chang, J; Elsea, SH; Hwang, KK; Kuo, BS; Kusmik, WF; Poole, JC,
)
0.13
" Physiologically based pharmacokinetic (PB-PK) model parameters (metabolic rate constants and tissue partition coefficients) were determined in male and female B6C3F1 mice and were taken from the literature for the male and female Fischer 344 rats."( Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse.
Allen, BC; Andersen, ME; Fisher, JW; Gargas, ML, 1991
)
0.5
"A physiologically based pharmacokinetic (PB-PK) model was developed to describe trichloroethylene (TCE) kinetics in the lactating rat and nursing pup."( Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
Andersen, ME; Clewell, HJ; Fisher, JW; Taylor, DH; Whittaker, TA, 1990
)
0.48
"A physiologically based pharmacokinetic (PB-PK) model was developed to describe trichloroethylene (TCE) kinetics in the pregnant rat exposed to TCE by inhalation, by bolus gavage, or by oral ingestion in drinking water."( Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
Andersen, ME; Clewell, HJ; Fisher, JW; Taylor, DH; Whittaker, TA, 1989
)
0.48
" After termination of treatment the half-life of TCE was 12."( Pharmacokinetics of chloral hydrate poisoning treated with hemodialysis and hemoperfusion.
Buur, T; Larsson, R; Norlander, B, 1988
)
0.27
"The development and application of appropriate physiologically based pharmacokinetic (PBPK) models of chemical contaminants will provide a rational basis for risk assessment extrapolation."( Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans.
Allen, BC; Fisher, JW, 1993
)
0.54
" After intravenous administration, CH rapidly disappeared from blood with a terminal half-life ranging from 5 to 24 min."( Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice.
Abbas, RR; Fisher, JW; Kidney, JK; Seckel, CS, 1996
)
0.29
" The pharmacokinetic behavior of EB-125I-hEGF1-53 was, in fact, comparable to that of CT-125I-hEGF1-53."( Perturbation of epidermal growth factor clearance after radioiodination and its implications.
Kuo, BS; Nordblom, GD; Wright, DS, 1997
)
0.3
"A six-compartment physiologically based pharmacokinetic (PBPK) model for the B6C3F1 mouse was developed for trichloroethylene (TCE) and was linked with five metabolite submodels consisting of four compartments each."( A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.
Abbas, R; Fisher, JW, 1997
)
0.3
" The results of a study which examined the enterohepatic recirculation (EHC) of the principle TRI metabolites was used to develop a physiologically-based pharmacokinetic model for TRI, which includes enterohepatic recirculation of its metabolites."( Physiologically-based pharmacokinetic model for trichloroethylene considering enterohepatic recirculation of major metabolites.
Bull, RJ; Fisher, JW; Merdink, JL; Stenner, RD, 1998
)
0.3
" Blood, urine, and exhaled breath samples were collected for development of a physiologically based pharmacokinetic (PBPK) model for trichloroethylene and its two major P450-mediated metabolites, trichloroacetic acid and free trichloroethanol."( A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol.
Abbas, R; Fisher, JW; Mahle, D, 1998
)
0.71
"A physiologically based pharmacokinetic (PBPK) model for inhaled trichloroethylene (TCE) was developed for B6C3F1 mice."( Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice.
Burton, GA; Fisher, JW; Greenberg, MS, 1999
)
0.3
" Compartmental and physiologically based pharmacokinetic (PBPK) models have been developed for the uptake, distribution, and metabolism of TCE and the production, distribution, metabolism, and elimination of P450-mediated metabolites of TCE."( Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites.
Fisher, JW, 2000
)
0.31
"A physiologically based pharmacokinetic model for perchloroethylene was parameterized, calibrated and validated using anatomic, physiologic, biochemical and physicochemical data obtained from the literature."( The application of physiologically based pharmacokinetic modelling in the analysis of occupational exposure to perchloroethylene.
Loizou, GD, 2001
)
0.31
"3), whereas MCA modified the Cmax (x1."( Evaluation of the influence of chloroacetic acids on the pharmacokinetics of trihalomethanes in the rat.
Krishnan, K; St-Pierre, A; Tardif, R, 2003
)
0.32
" Leptin was cleared with a half-life estimate of 23 min."( Plasma clearance and tissue distribution of radiolabeled leptin in the chicken.
Ashwell, CM; Brocht, DM; Caperna, TJ; McMurtry, JP, 2004
)
0.32
" Several pharmacokinetic parameters were determined after intravenous injection of (125)I-C-1027 to mice."( Pharmacokinetics of C-1027 in mice as determined by TCA-RA method.
Huang, YR; Li, QS; Liu, CX; Liu, YP; Zhou, MJ, 2005
)
0.33
" The assay was applied to the analysis of samples from a pharmacokinetic study."( High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans.
Kwon, KI; Yun, MH, 2006
)
0.33
"Bayesian population analysis of a harmonized physiologically based pharmacokinetic (PBPK) model for trichloroethylene (TCE) and its metabolites was performed."( Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
Chiu, WA; Clewell, HJ; Hack, CE; Jay Zhao, Q, 2006
)
0.33
" When rats were subcutaneously administered PCN, an increase of biliary excretion clearance and distribution volume was observed for drugs such as MPP(+), metformin, and tetraethylammonium, although the effects on pharmacokinetic parameters were variable among the tested drugs."( Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats.
Higashi, R; Maeda, T; Nagata, K; Oyabu, M; Tamai, I; Yamazoe, Y; Yotsumoto, T, 2007
)
0.34

Compound-Compound Interactions

Twenty-four volunteers with postacne atrophic scars were randomly divided into 3 equal groups. To establish the radioisotope (125I) tracer method combined with trichloroacetic acid (TCA) precipitation for the determination of nerve growth factor (NGF) in mouse plasma.

ExcerptReferenceRelevance
"To reveal how the TCA Masque, used alone or in combination with Jessner's solution, helps minimize some of these problems while retaining efficacy."( The TCA Masque. A new cream formulation used alone and in combination with Jessner's solution.
Chiarello, SE; Resnik, BI; Resnik, SS, 1996
)
0.29
" When used in combination with Jessner's and 16."( The TCA Masque. A new cream formulation used alone and in combination with Jessner's solution.
Chiarello, SE; Resnik, BI; Resnik, SS, 1996
)
0.29
"To establish the radioisotope (125I) tracer method combined with trichloroacetic acid (TCA) precipitation for the determination of nerve growth factor (NGF) in mouse plasma."( [Isotope tracer combined with trichloroacetic acid precipitation method for determination of nerve growth factor concentration in mouse plasma].
Chen, L; Jiang, G; Tang, G; Wang, S; Zhang, Y, 1998
)
0.83
"Radioisotope tracer labelling method combined with TCA precipitation was used to determine NGF in mouse plasma."( [Isotope tracer combined with trichloroacetic acid precipitation method for determination of nerve growth factor concentration in mouse plasma].
Chen, L; Jiang, G; Tang, G; Wang, S; Zhang, Y, 1998
)
0.59
"The radioisotope tracer method combined with TCA precipitation is stable, sensitive and reliable."( [Isotope tracer combined with trichloroacetic acid precipitation method for determination of nerve growth factor concentration in mouse plasma].
Chen, L; Jiang, G; Tang, G; Wang, S; Zhang, Y, 1998
)
0.59
"To compare deep peeling using phenol and PCI combined with trichloroacetic acid (TCA) 20% in treating atrophic acne scars."( Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post-acne scars; a randomized controlled trial.
Abdel Hay, RM; El Garem, YF; Leheta, TM, 2014
)
0.87
"24 patients with post-acne atrophic scars were randomly divided into two groups; group 1 was subjected to one session of deep peeling using phenol, and group 2 was subjected to four sessions of PCI combined with TCA 20%."( Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post-acne scars; a randomized controlled trial.
Abdel Hay, RM; El Garem, YF; Leheta, TM, 2014
)
0.63
"Twenty-four volunteers with postacne atrophic scars were randomly divided into 3 equal groups according to performed procedure on each side of the face (microneedling by dermaroller alone or combined with platelet-rich plasma [PRP] or trichloroacetic acid [TCA] 15% peeling) and received 6 bi-weekly sessions of treatment."( Microneedling combined with platelet-rich plasma or trichloroacetic acid peeling for management of acne scarring: A split-face clinical and histologic comparison.
Abdel-Wahab, H; El-Domyati, M; Hossam, A, 2018
)
0.91
"To study and compare the therapeutic efficacy and side effects of a 35% glycolic acid (GA) full face peel alone or in combination with a 10% or 20% trichloroacetic acid (TCA) spot peel for facial melasma."( Comparative Efficacy of a 35% Glycolic Acid Peel Alone or in Combination With a 10% and 20% Trichloroacetic Acid Spot Peel for Melasma: A Randomized Control Trial.
Bhalla, M; Garg, S; Kaur, J; Kumar, A; Thami, GP, 2019
)
0.93
"Chemical peels with GA alone or in combination with TCA do result in a significant improvement in melasma, but the combination of the peels in the same sitting does not seem to have any additive or synergistic effect while they may increase the side effects."( Comparative Efficacy of a 35% Glycolic Acid Peel Alone or in Combination With a 10% and 20% Trichloroacetic Acid Spot Peel for Melasma: A Randomized Control Trial.
Bhalla, M; Garg, S; Kaur, J; Kumar, A; Thami, GP, 2019
)
0.73
" Both medium-depth chemical peels including 15% TCA in combination with 70% GA and 35% TCA alone proved to be useful for the removal of epidermal or superficial lesions and to improve the texture of photodamaged facial skin (grade II-III Glogau photoaged skin)."( Comparative study of 15% trichloroacetic acid peel combined with 70% glycolic acid and 35% trichloroacetic acid peel for the treatment of photodamaged facial skin in aging women.
Kubiak, M; Mucha, P; Rotsztejn, H, 2020
)
0.86

Bioavailability

ExcerptReferenceRelevance
"36 h, respectively, and the bioavailability rate after subcutaneous administration was 47%."( Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats.
Kato, K; Kitajima, SI; Misaizu, T; Mitsuoka, C; Ogata, H; Shindo, H; Yoshioka, E, 2007
)
0.34
" The dose-dependent bioavailability of TCA in B6C3F1 mice exposed to TCA in drinking water was estimated by optimizing the fit of time course blood, plasma, and liver TCA concentrations for TCA doses ranging from 12 to 800 mg/(kg day) to predictions of a previously published TCA PBPK model."( Contribution of trichloroacetic acid to liver tumors observed in perchloroethylene (perc)-exposed mice.
Dugard, PH; Gargas, ML; Kirman, CR; Sweeney, LM, 2009
)
0.7
" Exposure to HAAs is influenced by consumption patterns and diet of individuals thus their bioavailability is an important parameter to the overall toxicity."( In vitro bioacessibility and transport across Caco-2 monolayers of haloacetic acids in drinking water.
Faria, MA; Ferreira, IMPLVO; Mansilha, C; Melo, A; Pinto, E, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Pretreatment of male B6C3F1 mice with clofibric acid (CFA) or trichloroacetic acid (TCA) in the drinking water results in a marked decrease in the lipoperoxidative response as measured by the production of thiobarbituric acid reactive substances.

ExcerptRelevanceReference
"We compared the fractionations obtained by three different methods of dosage of thyroid hormones and we concluded that trichloracetic PBI is very rapid, (about 15 minutes) excluding the length of calculation of radio activity), is easy to execute, and uses inexpensive materials."( [Study of thyroid function using diverse methods of separation of plasma radioiodine compounds in rats].
Rostami, P, 1976
)
0.26
" We examined the in vivo adduction of the blood proteins hemoglobin (Hb) and albumin in rats and mice dosed orally with [14C]trichloroethylene ([14C]TRI) to explore the development of a protein adduct biomarker of TRI exposure."( Adduction of hemoglobin and albumin in vivo by metabolites of trichloroethylene, trichloroacetate, and dichloroacetate in rats and mice.
Bull, RJ; Eyre, RJ; Stevens, DK, 1992
)
0.28
" Males pretreated with MCA had 45-fold greater plasma alanine aminotransferase (ALT) compared to the saline pretreated group similarly dosed with CHCl3."( Sex differences in monochloroacetate pretreatment effects on chloroform toxicity in rats.
Berndt, WO; Davis, ME, 1992
)
0.28
" Within the first 4 h following dosing there was no evidence of binding to DNA or other macromolecules in plasma and very little 'covalent' binding was detected in liver, indicating that at times when maximum DNA single-strand breakage has been reported there was no significant binding to liver cells."( Trichloroacetic acid: studies on uptake and effects on hepatic DNA and liver growth in mouse.
Coutts, C; Styles, JA; Wyatt, I, 1991
)
1.72
"568 liter/kg) for TCA in the lactating dam were estimated from both intravenous dosing studies and an inhalation study with TCE."( Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
Andersen, ME; Clewell, HJ; Fisher, JW; Taylor, DH; Whittaker, TA, 1990
)
0.48
" Animals were dosed by oral intubation on gestation days 6-15 (plug = 0) with 0, 330, 800, 1,200, or 1,800 mg/kg/day."( Teratogenic activity of trichloroacetic acid in the rat.
Randall, JL; Read, EJ; Smith, MK; Stober, JA, 1989
)
0.58
"0024/hour) were estimated both from intravenous dosing studies with TCA and from an inhalation study with TCE."( Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid.
Andersen, ME; Clewell, HJ; Fisher, JW; Taylor, DH; Whittaker, TA, 1989
)
0.48
" Dosing F344 rats with 200 mg/kg TCA in water or corn oil for 10 days increased peroxisome proliferation 179 and 278%, respectively, above the vehicle controls."( Species and strain sensitivity to the induction of peroxisome proliferation by chloroacetic acids.
Daniel, FB; DeAngelo, AB; McMillan, L; Savage, RE; Wernsing, P, 1989
)
0.28
" Comparison between single and fractionated dosing revealed the single dosing to be more effective cytogenetically."( Relative genotoxicity of trichloroacetic acid (TCA) as revealed by different cytogenetic assays: bone marrow chromosome aberration, micronucleus and sperm-head abnormality in the mouse.
Behera, BC; Bhunya, SP, 1987
)
0.58
"Detailed analysis of urine from two strains of rats and mice dosed po with trichloroethylene at four doses from 10 to 2000 mg/kg failed to detect any major species or strain differences in the metabolism of trichloroethylene."( Species differences in response to trichloroethylene. II. Biotransformation in rats and mice.
Green, T; Prout, MS, 1985
)
0.27
" Peak concentrations of the metabolites were reached within 2 hr of dosing in the mouse compared to 10 to 12 hr in the rat."( Species differences in response to trichloroethylene. I. Pharmacokinetics in rats and mice.
Green, T; Prout, MS; Provan, WM, 1985
)
0.27
" In vitro exposure of fetal limbs to various doses of 9-mePGA resulted in a significant increase in the accumulation of labeled GAG by fetal forelimbs at the high and intermediate dosage levels."( In vitro effects of the teratogen and folic acid antagonist, 9-methyl pteroylglutamic acid, on glycosaminoglycan accumulation in fetal rat limbs.
Abbott, K; Cotler, JM; Schmidt, RR, 1982
)
0.26
" In order to evaluate the interactive toxicity of t-butyl alcohol (TBA) with TCA, young male Wistar rats were dosed through water at a dose level of TBA (0."( Administration of subtoxic doses of t-butyl alcohol and trichloroacetic acid to male Wistar rats to study the interactive toxicity.
Acharya, S; Krishnan, S; Mehta, K; Pereira, J; Rao, CV; Rodrigues, S, 1995
)
0.54
"0 g/l, and CAA to CTA was present in 29% and 34% of the two dosage groups respectively."( Ras oncogene activation during hepatocarcinogenesis in B6C3F1 male mice by dichloroacetic and trichloroacetic acids.
DeAngelo, AB; Ferreira-Gonzalez, A; Garrett, CT; Nasim, S, 1995
)
0.51
"Pretreatment of male B6C3F1 mice with clofibric acid (CFA) or trichloroacetic acid (TCA) in the drinking water results in a marked decrease in the lipoperoxidative response as measured by the production of thiobarbituric acid reactive substances (TBARS) in mouse liver homogenates following acute dosing with TCA or dichloroacetic acid (DCA)."( Modification of lipoperoxidative effects of dichloroacetate and trichloroacetate is associated with peroxisome proliferation.
Austin, EW; Bull, RJ; Larson, JL; Okita, JR; Okita, RT, 1995
)
0.53
" Fischer 344 rats and beagle dogs were dosed orally with TRI and blood was analyzed for TRI, DCA, TCA, and trichloroethanol (TCE)."( Factors affecting species differences in the kinetics of metabolites of trichloroethylene.
Bonate, PL; Bull, RJ; Stenner, RD; Stevens, DK; Templin, MV; Tuman, D, 1995
)
0.29
" No statistically or biologically significant increases in the incidence of micronucleated polychromatic erythrocytes compared with the solvent control dosed animals were observed in either sex at the 6 h sampling time or in the females at the 24 h sampling time."( Trichloroacetic acid: investigation into the mechanism of chromosomal damage in the in vitro human lymphocyte cytogenetic assay and the mouse bone marrow micronucleus test.
Coutts, C; Fox, DA; Fox, V; Griffiths, K; Howard, CA; Mackay, JM; Styles, JA; Wyatt, I, 1995
)
1.73
" Mice were dosed with 67."( Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice.
Abbas, RR; Fisher, JW; Kidney, JK; Seckel, CS, 1996
)
0.29
" Jugular vein, duodenum, and bile duct-cannulated Fischer 344 rats were used, with the collection of blood, bile, urine, and feces samples after intraduodenal and intravenous dosing of animals with TRI, TCEOH, and TCA."( Enterohepatic recirculation of trichloroethanol glucuronide as a significant source of trichloroacetic acid. Metabolites of trichloroethylene.
Bull, RJ; Merdink, JL; Springer, DL; Stenner, RD; Stevens, DK, 1997
)
0.52
" Differences in dose-response curves, progression to cancer, and postexposure regression of lesions suggest that TCA and DCA work through different mechanisms."( Dissimilar characteristics of N-methyl-N-nitrosourea-initiated foci and tumors promoted by dichloroacetic acid or trichloroacetic acid in the liver of female B6C3F1 mice.
Latendresse, JR; Pereira, MA,
)
0.34
" For oral bolus dosing of TCE with 300, 600, and 2000 mg/kg, model predictions of TCE and several metabolites were in general agreement with observations."( A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.
Abbas, R; Fisher, JW, 1997
)
0.3
" In order to evaluate the interactive toxicity of t-butyl alcohol with trichloroacetic acid, young male Wistar rats were dosed through water at a dose level of t-butyl alcohol (TBA)-0."( A histopathological study of liver and kidney in male Wistar rats treated with subtoxic doses of t-butyl alcohol and trichloroacetic acid.
Acharya, S; Krishnan, S; Mehta, K; Pereira, J; Rao, CV; Rodriguez, S, 1997
)
0.74
" The IPRL system was dosed with either 5 or 50 micromol of either TCA or DCA (25 or 250 microM initial concentration, respectively)."( Kinetics of trichloroacetic acid and dichloroacetic acid in the isolated perfused rat liver.
Frazier, JM; Toxopeus, C, 1998
)
0.68
" Male B6C3F1 mice were dosed with TRI, CH, trichloroethanol (TCE), or TCA and metabolic profiles of each were determined."( The extent of dichloroacetate formation from trichloroethylene, chloral hydrate, trichloroacetate, and trichloroethanol in B6C3F1 mice.
Bull, RJ; Gonzalez-Leon, A; Merdink, JL; Schultz, IR, 1998
)
0.3
" Soybean oil is commonly used as a dosing vehicle for RA teratology studies and was also used in this study as a dosing vehicle for TCE."( Trichloroethylene, trichloroacetic acid, and dichloroacetic acid: do they affect fetal rat heart development?
Channel, SR; Eggers, JS; Fisher, JW; Goodyear, CD; Graeter, LJ; Johnson, PD; Latendresse, JR; MacMahon, KL; Sudberry, GL; Warren, DA,
)
0.46
" Additional male mice were dosed as described above and their livers were excised at 24, 48 h, and 7 days after the final dose."( Tumorigenicity of chloral hydrate, trichloroacetic acid, trichloroethanol, malondialdehyde, 4-hydroxy-2-nonenal, crotonaldehyde, and acrolein in the B6C3F(1) neonatal mouse.
Bucci, TJ; Chou, MW; Fu, PP; Kadlubar, FF; Samokyszyn, VM; Von Tungeln, LS; Yi, P, 2002
)
0.59
" Mice were dosed with chloral hydrate at 0, 50, 100, 250, 500, and 1000 mg/kg daily, 5 days/week, by aqueous gavage for 2 weekly dosing cycles."( Toxicokinetics of chloral hydrate in ad libitum-fed, dietary-controlled, and calorically restricted male B6C3F1 mice following short-term exposure.
Agrawal, N; Allaben, WT; Horsley, ET; Leakey, JE; Leakey, TI; Scherer, EM; Seng, JE; Xia, S, 2003
)
0.32
" However at the end of the first growing season needles of saplings exposed to 10 or 100 microg l(-1) foliage-applied TCA showed significantly more visible damage, higher activities of some detoxifying enzymes, lower protein contents and poorer water control than needles of saplings dosed with the same TCA concentrations to the soil."( Trichloroacetic acid cycling in Sitka spruce saplings and effects on sapling health following long term exposure.
Cape, JN; Dickey, CA; Heal, KV; Heal, MR; Koren, R; Schröder, P; Stidson, RT, 2004
)
1.77
" On the other hand, tissue repair showed a dose-response leading to regression of injury."( Dose-dependent liver regeneration in chloroform, trichloroethylene and allyl alcohol ternary mixture hepatotoxicity in rats.
Anand, SS; Mehendale, HM; Mumtaz, MM, 2005
)
0.33
" In particular, we investigated the effects of both toxicants on vimentin, at both the RNA and protein levels, using dose-response and time course curves."( Effects of trichloroethylene and its metabolite trichloroacetic acid on the expression of vimentin in the rat H9c2 cell line.
Caldwell, PT; Johnson, PD; Runyan, RB; Selmin, O; Thorne, PA, 2005
)
0.58
" This analysis provides an important step toward estimating uncertainty of dose-response relationships in noncancer and cancer risk assessment, improving the extrapolation of toxic TCE doses from experimental animals to humans."( Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
Chiu, WA; Clewell, HJ; Hack, CE; Jay Zhao, Q, 2006
)
0.33
" Tissue injury was measured during the dosing regimen (0, 1, 7, 14, and 30 days) and over a time course of 24-96h after the last dose (30 days)."( Impact of repeated exposure on toxicity of perchloroethylene in Swiss Webster mice.
Latendresse, JR; Mehendale, HM; Mumtaz, MM; Philip, BK, 2007
)
0.34
" The studies provide dose-response data on the development of hepatocellular neoplasia in male mice over a lifetime exposure to TCA."( The induction of hepatocellular neoplasia by trichloroacetic acid administered in the drinking water of the male B6C3F1 mouse.
Daniel, FB; DeAngelo, AB; George, MH; Wong, DM, 2008
)
0.61
" Based on similarities of TCE and TCA to typical PP, including dose-response characteristics showing PPARalpha-dependent responses coincident with liver tumor induction and abolishment of TCE and TCA effects in PPARalpha-null mice, the WOE supports the hypothesis that PPARalpha plays a dominant role in TCE- and TCA-induced hepatocarcinogenesis."( Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites.
Corton, JC, 2008
)
0.35
" 2000 ppm dosage of TCA was administered orally to 6 male rats ad libitum during the tests for 52 days consecutively."( Determination hematotoxic and hepatotoxic effects of trichloroacetic acid at sublethal dosage in rats.
Celik, I; Temur, A, 2009
)
0.6
" Benchmark dose analyses were conducted to determine the dose-response relationship between liver TCA AUC and the additional risk of hepatocellular adenomas or carcinomas (combined) in mice ingesting TCA."( Contribution of trichloroacetic acid to liver tumors observed in perchloroethylene (perc)-exposed mice.
Dugard, PH; Gargas, ML; Kirman, CR; Sweeney, LM, 2009
)
0.7
" Biomarkers selected for immunotoxic monitoring were the activities of adenosine deaminase (ADA) and myeloperoxidase (MPO) in various tissues of rats exposed to 2000 parts per million (ppm) dosage of TCA for 52 days."( Evaluation of neurotoxic and immunotoxic effects of trichloroacetic acid on rats.
Celik, I; Isik, I; Kaya, MS, 2010
)
0.61
" and gavage dosing of TCA and from TCA produced from TCE, it was concluded that TCA accounted for only about one-fifth of the degree of hepatomegaly produced by TCE."( Trichloroacetic acid: updated estimates of its bioavailability and its contribution to trichloroethylene-induced mouse hepatomegaly.
Chiu, WA, 2011
)
1.81
" We have examined the dose-response relationship for formic aciduria in male and female Fischer 344 rats, the effect of some known metabolites of TCE and examined the response in male Wistar rats to help understand its relevance to renal toxicity."( Trichloroethylene-induced formic aciduria: effect of dose, sex and strain of rat.
Evans, AR; Lock, EA; Yaqoob, N, 2013
)
0.39
" Oral dosing with TCE was conducted in subacute (600 mg/kg/d; 5 d; 7 inbred mouse strains) and subchronic (100 or 400 mg/kg/d; 1, 2, or 4 wk; 2 inbred mouse strains) designs."( Comparative analysis of the relationship between trichloroethylene metabolism and tissue-specific toxicity among inbred mouse strains: liver effects.
Ball, LM; Bodnar, WM; Bradford, BU; Collins, LB; Gold, A; Kosyk, O; Rusyn, I; Shymonyak, S; Uehara, T; Yoo, HS, 2015
)
0.42
" Oral dosing with TCE was conducted in subacute (600 mg/kg/d; 5 d; 7 inbred mouse strains) and subchronic (100 or 400 mg/kg/d; 1, 2, or 4 wk; 2 inbred mouse strains) designs."( Comparative analysis of the relationship between trichloroethylene metabolism and tissue-specific toxicity among inbred mouse strains: kidney effects.
Ball, LM; Bodnar, WM; Bradford, BU; Collins, LB; Gold, A; Kosyk, O; Rusyn, I; Shymonyak, S; Uehara, T; Yoo, HS, 2015
)
0.42
" Dose-response analysis of gene expression at the pathway level yielded points of departure similar to those derived from the traditional toxicology studies for both non-cancer and cancer effects."( Population-based dose-response analysis of liver transcriptional response to trichloroethylene in mouse.
Aylor, DL; Chiu, WA; House, JS; Konganti, K; McKenney, C; Rusyn, I; Threadgill, DW; Venkatratnam, A; Wright, FA, 2018
)
0.48
" It also revealed that treatment of L-02 cells with TCA induced decreased in DNMT1 and DNMT3a mRNA and protein levels with a time-dependent manner and a dose-response relationship, while DNMT3b had no obvious change."( DNA methyltransferase expression and DNA hypomethylation status in human hepatocytes following trichloroacetic acid exposure.
Gao, J; Lai, C; Yang, J; Yuan, J; Zhang, W; Zhu, Z, 2019
)
0.73
" This new method can be applied for the pharmacokinetic analysis of TCS and its metabolites and the determination of the optimal TCS dosage in children."( Simple method to detect triclofos and its metabolites in plasma of children by combined use of liquid chromatography tandem-mass spectrometry and gas chromatography-mass spectrometry.
Hashimoto, S; Inoue, M; Ito, Y; Kamijima, M; Nakahira, Y; Nakajima, T; Sato, H, 2019
)
0.51
"After adjusting for relevant confounding factors, we observed positive dose-response relationships between blood Br-THM tertiles and urinary HNE-MA (P for trend < 0."( Blood and urinary biomarkers of prenatal exposure to disinfection byproducts and oxidative stress: A repeated measurement analysis.
Chen, YJ; Cheng, YH; Huang, LL; Liu, C; Liu, EN; Lu, WQ; Messerlian, C; Sun, Y; Wang, YX, 2020
)
0.56
" On the basis of Investigator's Global Assessment (IGA), clinical polarized photography (CPP), colorimetry and Skindex, we experimentally determined an optimum TCA concentration and assessed our model's ability to exhibit a dose-response relationship between degree of inciting insult and severity of resulting pigmentation."( An in vivo model of postinflammatory hyperpigmentation and erythema: clinical, colorimetric and molecular characteristics.
Al-Jamal, M; Braunberger, T; Hamzavi, IH; Isedeh, P; Karaman-Jurukovska, N; Kohli, I; Lim, HW; Lyons, AB; Matsui, M; Mi, QS; Mohammad, TF; Nahhas, AF; Nartker, N; Nicholson, C; Vellaichamy, G; Yin, C; Zhou, L; Zubair, R, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency31.62280.01846.806014.1254AID624172
GLI family zinc finger 3Homo sapiens (human)Potency68.58960.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency31.22760.000221.22318,912.5098AID1259247; AID588516
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency40.36540.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency53.10050.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.83680.000817.505159.3239AID1159527; AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency59.57970.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency56.56880.000229.305416,493.5996AID743069; AID743078
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency0.00630.316212.443531.6228AID924
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
Integrin beta-3Homo sapiens (human)Potency0.00630.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency0.00630.316211.415731.6228AID924
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (70)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID384213Mutagenic activity in Salmonella Typhimurium TA100 without metabolic activation2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,116)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901803 (57.86)18.7374
1990's370 (11.87)18.2507
2000's441 (14.15)29.6817
2010's389 (12.48)24.3611
2020's113 (3.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 106.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index106.00 (24.57)
Research Supply Index8.13 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index201.64 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (106.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials107 (3.25%)5.53%
Reviews89 (2.70%)6.00%
Case Studies99 (3.00%)4.05%
Observational2 (0.06%)0.25%
Other3,000 (90.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]